We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

12 hedge funds and large institutions have $2.18M invested in AIM ImmunoTech in 2013 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $2.09M → $2.18M (+$90K)

14% less funds holding

Funds holding: 14 → 12 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
12
Holders Change
-2
Holders Change %
-14.29%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BIT
BlackRock Institutional Trust
California
+$36.2K
2
WS
Wedbush Securities
California
+$36.2K

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$72.5K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$60.4K
3
Renaissance Technologies
Renaissance Technologies
New York
-$60.4K
4
Citadel Advisors
Citadel Advisors
Florida
-$25K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$24.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$938K -$24.2K -2 -3%
BIT
2
BlackRock Institutional Trust
California
$631K +$36.2K +3 +7%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$149K – – –
Jacobs Levy Equity Management
4
Jacobs Levy Equity Management
New Jersey
$139K -$60.4K -5 -33%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$76K – – –
Northern Trust
6
Northern Trust
Illinois
$65K – – –
WS
7
Wedbush Securities
California
$41K +$36.2K +3 New
Renaissance Technologies
8
Renaissance Technologies
New York
$30K -$60.4K -5 -71%
BTS
9
BB&T Securities
Virginia
$27K – – –
State Street
10
State Street
Massachusetts
$24K – – –
GC
11
Guggenheim Capital
Illinois
$18K – – –
VKH
12
Virtu KCG Holdings
New York
$9K – – –
Bank of America
13
Bank of America
North Carolina
$8K – – –
Goldman Sachs
14
Goldman Sachs
New York
$6K – – –
JIC
15
Joel Isaacson & Co
New York
$4K -$12.1K -1 Closed
ICAS
16
Investors Capital Advisory Services
Massachusetts
$4K – – –
BA
17
BlackRock Advisors
Delaware
$3K – – –
U
18
UBS
Switzerland
$3K – – –
Wells Fargo
19
Wells Fargo
California
$3K – – –
CHC
20
City Holding Co
West Virginia
$1K – – –
Deutsche Bank
21
Deutsche Bank
Germany
– -$72.5K -6 Closed
Citadel Advisors
22
Citadel Advisors
Florida
– -$25K -2 Closed

AIM Hedge Fund Activity: Q4 2013 in Review

12 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2013, worth a combined $2.18M — up 4.3% from $2.09M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of AIM and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $36.2K. The largest seller was Deutsche Bank, exiting entirely with an estimated $72.5K sold.

  • 12 institutional investors held AIM ImmunoTech (AIM) as of Q4 2013, down from 14 in Q3 2013.
  • Funds reported $2.18M of AIM ImmunoTech stock for Q4 2013, up 4.3% quarter-over-quarter.
  • 1 fund opened new AIM ImmunoTech positions in Q4 2013 and 3 closed out, a net change of -2 holders.
  • The largest AIM ImmunoTech buyer in Q4 2013 was BlackRock Institutional Trust, an estimated $36.2K added.
  • The largest AIM ImmunoTech seller in Q4 2013 was Deutsche Bank, an estimated $72.5K sold.

Based on aggregated 13F filings for Q4 2013.